Padlock Therapeutics Obtains $23,000,000 Series A Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=80a69791-324c-44c4-97d2-52d937d8ff17 - Date
12/19/2014 - Company Name
Padlock Therapeutics - Mailing Address
25 First Street Cambridge, MA 02141 USA - Company Description
At Padlock, we’re taking a whole new approach to treating destructive autoimmune diseases by extinguishing autoantigens at their source instead of targeting the immune system like current medicines. - Website
http://www.padlocktherapeutics.com - Transaction Type
Venture Equity - Transaction Amount
$23,000,000 - Transaction Round
Series A - Proceeds Purposes
Padlock plans to use the proceeds from this financing to deepen its understanding of the role of protein-arginine deiminases (PADs) in autoimmune disease and to advance its pipeline of PAD-directed therapeutics. - M&A Terms
- Venture Investor
